Merck & Co. stock gets HIV pipeline catalyst ahead of Glasgow data

Published on 11/03/2026 at 16:27 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Merck & Co. stock enters a new catalyst window as the company prepares fresh HIV treatment and prevention data. FDA review also advances.

HIV pipeline opens next catalyst window

Merck will present treatment and prevention data at HIV Drug Therapy Glasgow from November 8 to 11.
The FDA accepted two supplemental applications for IDVYNSO, with a target action date in April 2027.
Adult enrollment has finished in both Phase 3 trials testing monthly oral alimatravir for HIV prevention.

Merck & Co., US58933Y1055, Illustration mit AI erstellt.

Merck & Co. is adding a new HIV pipeline catalyst to the earnings and oncology developments covered in its latest report. In a November 2 release, the drugmaker said it will present treatment and prevention data at HIV Drug Therapy Glasgow from November 8 to 11.

New HIV data move into focus

The program includes the approved once-daily IDVYNSO regimen, investigational once-weekly oral combinations of islatravir with lenacapavir or ulonivirine, and the investigational once-monthly oral pre-exposure prophylaxis candidate alimatravir, also known as MK-8527.

Merck said the conference will include Week 48 subgroup analyses for the Phase 3 ISLEND-1 and ISLEND-2 studies of once-weekly islatravir and lenacapavir. ISLEND-2 will also provide patient-reported outcomes and a qualitative assessment of participant and provider experiences with weekly dosing. The company is collaborating with Gilead Sciences on that combination.

The official Merck release also says adult enrollment is complete in both Phase 3 trials evaluating alimatravir as a possible monthly oral prevention option. The company plans to present participant demographics from EXPrESSIVE-10 and EXPrESSIVE-11, while the trials remain under evaluation for safety and efficacy.

Regulatory timing adds visibility

The U.S. Food and Drug Administration has accepted two supplemental New Drug Applications for IDVYNSO. One application covers data from previously untreated adults, while the other seeks to add 96-week data for virologically suppressed adults. The agency set April 22, 2027, as the target action date for both applications.

The real-time quote of Merck & Co. stock showed Merck & Co. stock trading at 129.75 euros on Lang & Schwarz at 16:12 CET on Tuesday, November 3, 2026.